Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

90 evidence topics · 49 sources

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.